NCT04466761TerminatedPhase 1
Phase I Ascending Dose Study of Dietary Supplementation With Glycan Monomers in Healthy Adults
University of California, Davis2 sites in 1 country14 target enrollmentStarted: June 23, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 14
- Locations
- 2
- Primary Endpoint
- Characterize Immunoglobulin fragment crystallization modifications
Study Overview
Brief Summary
The investigators will conduct a parallel-group, placebo-controlled, randomized, double-blind ascending dose Phase I study of dietary supplementation in healthy individuals to evaluate safety and to determine the pharmacologically effective dose (ED).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients must be 18-45 years of age
- •Patients who are in general good health
- •Body Mass Index (BMI) range of 18.5-25
- •All individuals must have the ability to provide inform consent
Exclusion Criteria
- •Women who are pregnant, actively nursing, or pregnant within the last year
- •Women who are peri-menopausal or post-menopausal
- •Women with irregular menstrual cycles (more frequently than every 21 days or lasts longer than 8 days (missed, early, or late periods are also considered signs of an irregular cycle).
- •Women on hormonal contraception, including birth control, hormonal intrauterine device, or contraceptive implant
- •Past medical history of an autoimmune condition or malignancy, excluding non-melanoma skin cancer
- •Individuals with first degree relative with history of an autoimmune condition
- •Individuals with cardiovascular, pulmonary, reproductive, endocrine, metabolic, neurologic, gastrointestinal, hematologic, or infectious diseases of any kind
- •Individuals with diagnosis of galactosemia or congenital disorders of glycosylation
- •Individuals with phenylketonuria
- •Individuals currently taking prescription medications, or have taken prescription medications within the last 3 months
- •Individuals currently taking over the counter medications
- •Individuals currently taking or have taken supplements including herbal, protein or vitamin supplements in the last 3 months (e.g. whey protein, St. John's Wort, green tea supplements, biotin, creatine supplements), excluding multivitamins or essential vitamins
- •Individuals with prior history of severe food or drug allergic reactions
- •Individuals with a diagnosis of type I or II diabetes mellitus
- •Individuals with allergic reaction or adverse reaction to shellfish, N-acetyl glucosamine, galactose, or Spirulina/chlorella/algae supplements
- •Individuals with social history of current use of tobacco, alcohol or other drugs
- •Individuals with dietary restrictions (vegetarians are permitted to participate in the study) or to whom any of the following dietary habits or characteristics apply (the following exclusion criteria are placed to minimize variability in diet in our study population):
- •Actively dieting or trying to lose weight
- •Vegan diet
- •Consume equal to or greater than 2 cups of tea a day
- •Consume equal to or greater than 4 cups of coffee a day
- •Consume equal to or greater than 3 cups of fruit juice a day
- •Practice intensive exercise patterns (marathon training, workouts >4 hours a day)
- •Consume soda or energy drinks of any amount
- •On a carbohydrate-restricted or "Paleo" diet
- •Calorie-restricted diet (less than 20%-25% of maintenance calories)
Outcomes
Primary Outcomes
Characterize Immunoglobulin fragment crystallization modifications
Time Frame: 4 Weeks
Use mass spectrometry and RNA sequencing from subject blood samples to characterize site specific glycosylation on Immunoglobulin A, Immunoglobulin M, and Immunoglobulin G.
Identify the maximum effective dose
Time Frame: 16 Weeks
Identify maximum effective dose of dietary supplement in grams/day.
Secondary Outcomes
- Quantification of enzymatic modifications measured in grams by spectrometry(6 Months)
- Transcriptome analysis to determine the effect of dietary supplementation on the immune system(6 Months)
- Assess for potential adverse events(2 Months after first dose)
- Flow cytometry to determine the effect of dietary supplementation on the immune system(6 Months)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy VolunteersArthritis, RheumatoidNCT03315494Oscotec Inc.24
Completed
Phase 1
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BHuntington DiseaseNCT03787758Supernus Pharmaceuticals, Inc.6
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy SubjectsHealthyNCT05043792TransThera Sciences (Nanjing), Inc.20
Completed
Phase 1
A Multiple Ascending Dose Study of ETC-1002 in Healthy SubjectsSafety Evaluation of Escalating DosesNCT01485146Esperion Therapeutics, Inc.24
Completed
Phase 1
Safety and Tolerability of GX-I7 in HPV-infected Female VolunteersHuman PapillomavirusNCT03144934Genexine, Inc.32